14.74
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$14.86
Aprire:
$14.73
Volume 24 ore:
43,832
Relative Volume:
0.51
Capitalizzazione di mercato:
$306.48M
Reddito:
$306.91M
Utile/perdita netta:
$-59.11M
Rapporto P/E:
-98.27
EPS:
-0.15
Flusso di cassa netto:
$6.35M
1 W Prestazione:
-0.07%
1M Prestazione:
-2.77%
6M Prestazione:
-1.73%
1 anno Prestazione:
+21.74%
Amarin Corp Adr Stock (AMRN) Company Profile
Nome
Amarin Corp Adr
Settore
Industria
Telefono
353 1 6699 020
Indirizzo
SPACES SOUTH DOCKLANDS, BLOCK C, DUBLIN 2
Compare AMRN vs LLY, JNJ, ABBV, AZN, NVS
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
|
AMRN
Amarin Corp Adr
|
14.74 | 308.98M | 306.91M | -59.11M | 6.35M | -0.15 |
|
LLY
Lilly Eli Co
|
1,040.00 | 929.27B | 65.18B | 20.64B | 6.44B | 22.96 |
|
JNJ
Johnson Johnson
|
243.45 | 589.19B | 94.19B | 26.80B | 19.70B | 11.05 |
|
ABBV
Abbvie Inc
|
231.50 | 402.08B | 61.16B | 4.20B | 19.68B | 2.3671 |
|
AZN
Astrazeneca Plc
|
205.55 | 317.06B | 58.80B | 10.24B | 8.98B | 3.2788 |
|
NVS
Novartis Ag Adr
|
163.10 | 307.56B | 54.72B | 14.02B | 15.32B | 7.1855 |
Amarin Corp Adr Stock (AMRN) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2023-11-20 | Ripresa | JP Morgan | Underweight |
| 2023-10-25 | Downgrade | Jefferies | Buy → Hold |
| 2023-01-06 | Aggiornamento | Jefferies | Hold → Buy |
| 2022-05-06 | Downgrade | JP Morgan | Neutral → Underweight |
| 2022-05-05 | Downgrade | H.C. Wainwright | Buy → Neutral |
| 2022-05-05 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| 2022-05-04 | Downgrade | Northland Capital | Outperform → Market Perform |
| 2021-05-12 | Downgrade | Goldman | Neutral → Sell |
| 2020-09-29 | Ripresa | JP Morgan | Neutral |
| 2020-08-26 | Iniziato | Piper Sandler | Overweight |
| 2020-05-05 | Iniziato | Northland Capital | Outperform |
| 2020-03-31 | Downgrade | Goldman | Buy → Neutral |
| 2020-03-31 | Downgrade | Jefferies | Buy → Hold |
| 2020-03-31 | Aggiornamento | Oppenheimer | Underperform → Perform |
| 2020-03-13 | Aggiornamento | Goldman | Neutral → Buy |
| 2020-03-02 | Iniziato | Cowen | Outperform |
| 2020-02-18 | Aggiornamento | Citigroup | Neutral → Buy |
| 2020-01-06 | Iniziato | JP Morgan | Neutral |
| 2019-12-16 | Downgrade | Stifel | Buy → Hold |
| 2019-11-20 | Iniziato | Oppenheimer | Underperform |
| 2019-11-18 | Downgrade | Citigroup | Buy → Neutral |
| 2019-11-15 | Reiterato | SVB Leerink | Outperform |
| 2019-10-31 | Iniziato | Aegis Capital | Buy |
| 2019-10-15 | Iniziato | Goldman | Neutral |
| 2019-08-14 | Iniziato | SVB Leerink | Outperform |
| 2019-07-09 | Reiterato | Jefferies | Buy |
| 2019-06-17 | Iniziato | ROTH Capital | Buy |
| 2019-03-22 | Iniziato | Stifel | Buy |
Mostra tutto
Amarin Corp Adr Borsa (AMRN) Ultime notizie
BioNTech (BNTX) Soars 11.8%: Is Further Upside Left in the Stock? - Yahoo Finance
Amarin Corporation (AMRN) Announces Select Unaudited Financial Highlights - Finviz
AMRN Stock Up 17% as Preliminary Q4 Sales Beat Expectations - Finviz
China Universal Asset Management Co. Ltd. Sells 76,302 Shares of Amarin Corporation PLC $AMRN - Defense World
Net current asset value per share of Amarin Corporation Plc Sponsored ADR – MUN:EH3 - TradingView — Track All Markets
Companies Like Amarin (NASDAQ:AMRN) Are In A Position To Invest In Growth - Sahm
Tops & Flops Stocks - sharewise.com
RECORDATI FIRST NINE MONTHS 2025 RESULTS: REVENUE +12.2%, EBITDA(1) +11.8%, ADJUSTED NET INCOME(2) +10.7%; ISTURISA PEAK SALES ESTIMATE DOUBLED TO GREATER THAN € 1.2 BILLION - GlobeNewswire Inc.
Amarin (AMRN) Unprofitable as Losses Worsen, Profit Growth Forecasts Test Bullish Turnaround Hopes - Sahm
Leerink Partners raises Amarin stock price target to $12 on strong Q3 - Investing.com
Amarin Announces Plan to Initiate a Ratio Change Under Its American Depository Receipt (ADR) Program - ADVFN
Cash from operating activities of Amarin Corporation Plc Sponsored ADR – SWB:EH3 - TradingView
Amarin Corporation plc (NASDAQ:AMRN) Stock Catapults 25% Though Its Price And Business Still Lag The Industry - Sahm
Amarin Corporation plc Announces $17.8 Million Registered Direct Offering of American Depositary Shares - ADVFN
Amarin stock rises after ESC Congress data on VASCEPA mechanism - Investing.com
Earnings call transcript: Amarin Q2 2025 sees revenue beat, stock stable - Investing.com
Amarin's Q2 Earnings & Revenues Trump Estimates, Stock Rises - Yahoo Finance
Amarin Gears Up To Report Q2 Earnings: Here's What To Expect - Barchart.com
3 Strong Buy Breakout Stocks for Explosive Returns - The Globe and Mail
FDA Accepts Merck's Filing for Two-Drug, Once-Daily HIV Pill - Finviz
PROK Surges More Than 500% on Upbeat Data From Kidney Cell Therapy Study - Finviz
Amarin Soars 27% on Vazkepa Licensing Deal With Recordati in the EU - Nasdaq
Amarin Shares Surge After $175M European Licensing Deal For Heart Drug VAZKEPA - Sahm
Incyte Gets FDA Nod for the Expanded Use of Monjuvi in Lymphoma - Finviz
Is Amarin (AMRN) Stock Outpacing Its Medical Peers This Year? - Yahoo Finance
KURA Stock Rises More Than 15% This Past Week: Here's Why - The Globe and Mail
SNY's Rilzabrutinib Wins 4th Orphan Drug Tag for Sickle Cell Disease - Finviz
Kymera Stock Gains on Positive Data on Investigational Dermatitis Drug - Finviz
Is GSK PLC Sponsored ADR (GSK) Outperforming Other Medical Stocks This Year? - Yahoo Finance
VSTM Stock Soars 22% in a Month on Ovarian Cancer Combo Drug Approval - Finviz
Amarin Corp PLC Share Price ADR Each Rep 20 Ord Spon - Hargreaves Lansdown
Amarin announces ADS ratio change to meet Nasdaq requirements - Investing.com
Amarin adds investment expert Michael Torok to Board By Investing.com - Investing.com
Amarin urged to review strategy by major shareholders - Investing.com
The Market Doesn't Like What It Sees From Amarin Corporation plc's (NASDAQ:AMRN) Revenues Yet As Shares Tumble 26% - Sahm
Amarin Corp PLC (AMRN) Q4 2024 Earnings Call Highlights: Navigating Challenges and Expanding ... - Yahoo Finance
Amarin Plans Major ADR Restructuring: What This 1:20 Ratio Change Means for Investors - Stock Titan
Invesco Nasdaq Biotechnology ETF Holdings - Quiver Quantitative
Why Core & Main Shares Are Trading Lower By 11%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session - Investing.com UK
Free float of Amarin Corporation Plc Sponsored ADR – NASDAQ:AMRN - TradingView
symbol__ Stock Quote Price and Forecast - CNN
Sarissa Capital Calls for Amarin Special Meeting to Vote on Its Nominees - 24/7 Wall St.
Amarin CorpADR (AMRN) News, Articles, Events & Latest Updates - Stocktwits
Validea Kenneth Fisher Strategy Daily Upgrade Report9/24/2022 - Nasdaq
AMRN Forecast — Price Target — Prediction for 2026 - TradingView
HLS Announces that Vascepa® is now reimbursed by Ontario's Provincial Drug Plan - The Globe and Mail
Generic-Drug Labeling Strategy Likely to Survive Teva Rehearing - Bloomberg.com
The Daily Biotech Pulse: Amarin Vascepa Data, Galapagos Osteoarthritis Drug Update, 4 IPOs - Yahoo Finance
Amarin Stock Melts Down After Losing Patent Battle For Heart Drug - Investor's Business Daily
Amarin stock heads toward highest prices in more than a decade after new Vascepa FDA approval - MarketWatch
This Biotech Stock Just Got A Highly Anticipated FDA Approval - Investor's Business Daily
Amarin Corp Adr Azioni (AMRN) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):